Evidence map›Paper›PMID 40299184›Full record

ReviewMetabolic brain disease2025

A second act for spironolactone: cognitive benefits in renal dysfunction - a critical review.

Akhil Sharma, Ashi Mannan, Shareen Singh, Thakur Gurjeet Singh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Akhil SharmaChitkara College of Pharmacy, Chitkara University, 140401, Rajpura, Punjab, India.
Ashi MannanChitkara College of Pharmacy, Chitkara University, 140401, Rajpura, Punjab, India.
Shareen SinghChitkara College of Pharmacy, Chitkara University, 140401, Rajpura, Punjab, India.
Thakur Gurjeet SinghChitkara College of Pharmacy, Chitkara University, 140401, Rajpura, Punjab, India. gurjeet.singh@chitkara.edu.in.ORCID 0000-0003-2979-1590

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Renal dysfunction or Chronic kidney disease (CKD) are increasingly associated with cognitive deficit and memory impairment, suggesting a crucial kidney-brain axis. This review examines spironolactone's emerging role as a neuroprotective agent in the context of renal dysfunction-induced cognitive impairment. As a selective mineralocorticoid receptor (MR) antagonist, spironolactone demonstrates multifaceted protective mechanisms beyond its well established renoprotective effects. Evidences also suggests that spironolactone attenuates neuroinflammation, mitigates oxidative stress in brain, preserve blood-brain barrier (BBB) integrity and regulates hormonal imbalances associated with renal dysfunction. This review focuses on the reported beneficial effects of spironolactone in various neurodegenerative diseases (NDDs). These mechanisms collectively protect against the neurodegeneration in memory impairment induced by renal dysfunction. The dual action of spironolactone on both renal and cerebral tissues presents a novel therapeutic advantage in addressing this complex pathophysiology. This study elucidates multiple beneficial mechanisms by which spironolactone addresses cognitive impairment associated with renal dysfunction. Spironolactone enhances BBB protection and restores BBB integrity which is often compromised with renal dysfunction. It promotes neuroplasticity (allowing for improved neural adaptation and cognitive function), additionally mediates cerebral blood flow (CBF) ensuring adequate oxygen and nutrient delivery to brain. Spironolactone's anti-inflammatory effects by inhibiting the nuclear factor-kappa B (NF-κB) pathway and modulation of neuregulin1 (NRG1)/v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4 (ERBB4) signaling effectively reduce neuroinflammation that contributes to memory impairment. It also mitigates oxidative stress by targeting NADPH-oxidase (NOX), a major source of reactive oxygen species (ROS) in the central nervous system (CNS). Spironolactone also maintains hormonal balance, particularly regarding aldosterone levels, which become dysregulated in renal dysfunction and negatively impact brain function. These insights provide new possibilities for developing targeted therapies against renal dysfunction-induced memory impairment.

Indexed as

CognitionCognitive DysfunctionKidney DiseasesMineralocorticoid Receptor AntagonistsNeuroprotective AgentsRenal Insufficiency, ChronicSpironolactoneAnimalsBlood-Brain BarrierBrainHumansOxidative StressMineralocorticoid Receptor AntagonistsNeuroprotective AgentsSpironolactoneBlood-brain barrier (BBB) and memory impairmentMineralocorticoid receptor (MR) antagonistRenal-dysfunctionSpironolactone

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.